Hims Weight Loss in May 2026: Pricing, Sign-Up Process, and the Compounding Question

In April 2025 Novo Nordisk and Hims announced a partnership to sell brand-name Wegovy at $599/month. Ten weeks later Novo killed it. Eight months after that the FDA sent Hims a warning letter, five months after that Novo sued, and three weeks after the suit was filed the two sides settled and Hims agreed to stop selling compounded semaglutide.

That is the arc of Hims's GLP-1 business between April 2025 and March 2026, and it is why a 2026 reader asking "is Hims weight loss any good" needs a different answer to the one a 2024 reviewer would have given. The product on the shelf is not the product that was on the shelf a year ago. This is what we know from public sources about what Hims actually sells today, what it costs, and what to watch on the intake.

About this review (May 2026 edition)

This review is based on public Hims & Hers disclosures, SEC filings, FDA warning letters, court records, the Novo Nordisk press release of June 23, 2025, and the March 9, 2026 settlement announcement. We have not yet completed a hands-on sign-up. A hands-on update will be added as a dated block at the top of this page once our editorial team has run the intake end to end. Until then, every factual claim below is linked to a public source. We do not accept advertising from Hims or any other GLP-1 provider; our editorial policy is on the editorial policy page.

What Hims actually sells in the GLP-1 category, May 2026

For most of 2024 and 2025 the Hims GLP-1 product was compounded injectable semaglutide, disclosed in the company's Q3 FY2024 10-Q as a May 2024 launch. The legal framing was §503A(b)(1)(D) personalised-dose compounding, which we explain below.

That product is being wound down. Under the March 9, 2026 settlement with Novo Nordisk reported by HMP Global, Hims agreed to stop advertising compounded GLP-1 products in exchange for Novo dismissing its patent suit. New patients are routed to FDA-approved Wegovy and Ozempic at Novo's self-pay prices, with both injectable and oral Wegovy on offer per Hims's March 26, 2026 announcement. Existing compounded patients are being transitioned. Novo reserved the right to refile if Hims breaches the terms.

Pricing as advertised on Hims's site

The homepage headline as of May 2026 is "starting at $149/month" for the Wegovy oral pill. The "starting" language is doing real work; here is what the Hims press release and pricing pages disclose when read together:

• Wegovy oral pill (medication only): $149/month for cash-pay patients (all doses, introductory rate based on current published pricing).
• Wegovy injectable pen (medication only): $199/month for cash-pay patients.
• Ozempic injectable (0.5 mg, 1 mg, 2 mg): Novo's self-pay rate, currently around $499/month.
• Hims Weight Loss Membership: $39 for the first month, then $149/month on auto-renewal. This is billed separately from the medication.

The combined steady-state cost a new patient actually pays is therefore approximately $298/month for the oral pill (medication $149 + membership $149) or $348/month for the injectable (medication $199 + membership $149), after the introductory first-month membership rate of $39. The headline "starting at $149/month" refers only to the medication component and omits the mandatory membership fee. For a side-by-side look at Hims alongside other cash-pay telehealth providers, see our best cash-pay GLP-1 telehealth comparison.

For patients with commercial insurance and access to the Novo Nordisk Savings Card, the medication component can drop to as low as $0–$25/month, making the Hims-mediated insurance path significantly more cost-effective. The membership fee still applies regardless of insurance status.

For comparison context see our Wegovy cost without insurance page.

What patients say: Reddit signal on the Hims transition

Reddit communities (r/Semaglutide, r/Ozempic, r/WeightLoss) reflect a few consistent themes in discussions about Hims as of 2025–2026:

On the product itself: Users who stuck with or transitioned to branded Wegovy via Hims report real appetite suppression, with weight losses of 10–35 pounds commonly cited over several months. The clinical experience with branded Wegovy tracks the published trial data — which is expected, because it is the same product.

On operations and support: The most frequent complaints centre on the platform mechanics rather than the medication. Shipping delays, billing charges that process before medication ships, and difficulty reaching a human through what users describe as a chatbot-first support system appear repeatedly across threads. Cancellation friction — charges that continue after users believe they've cancelled — is another recurring theme, with multiple users describing the process as more difficult than expected.

On the cost transition: Patients who were previously on Hims compounded semaglutide and have been moved to branded Wegovy face a meaningful price increase. The $149–$199/month headline medication price plus the $149/month membership represents roughly double or more what many compounded patients were paying. Several threads include users who switched to other compounding-focused providers specifically because of this cost step-up after the transition.

These are patterns in public threads, not a representative survey. Individual experiences vary; some users describe the Hims support and logistics as smooth.

The legal pathway Hims said it was using

Until the March 2026 settlement, Hims's defence was §503A(b)(1)(D) of the Federal Food, Drug, and Cosmetic Act. In plain terms: a state-licensed pharmacist may compound a drug for an identified patient when the prescriber documents in writing that a change from the FDA-approved product produces "a significant difference" for that patient — an inactive-ingredient allergy, a non-commercial dose, or a combination preparation. Our compounded vs brand semaglutide guide explains what the finished-product differences actually mean for patients.

On the February 23, 2026 earnings call reported by STAT News, CEO Andrew Dudum told investors Hims would keep selling compounded GLP-1s under the personalised-dose framing. Three weeks later the settlement reversed that position. The pathway itself remains open to other compounders under the same statute; see the compounding cliff timeline.

What regulators and the manufacturer said about that

On September 9, 2025 FDA issued separate warning letters to Hims (716567) and Hers (716825). Both letters cited misleading marketing claims that the compounded products contained "the same active ingredient as Ozempic and Wegovy", and faulted Hims for promoting compounded drugs as if they were generically equivalent to the approved brand. Both letters also cited failure to submit required adverse-event reports.

In March 2026, the FDA issued a broader wave of more than 30 warning letters to telehealth providers and compounders marketing GLP-1 medications, signalling continued and expanding enforcement activity across the sector.

Novo Nordisk followed. On February 9, 2026 in the District of Delaware Novo filed a patent-infringement suit against Hims asserting U.S. Patent No. 8,129,343 (the semaglutide-compound patent, expiring December 2031). Companion suits hit fourteen other firms the same day.

The February 2026 oral-pill episode is the cleanest single illustration of the pressure: Hims announced a $49/month compounded semaglutide pill on February 5, 2026 and retracted it within roughly four days under FDA pressure and Novo's threatened legal action. The pill never reached steady-state sale.

The June 2025 Novo partnership and its termination

In April 2025 the two companies announced Hims would sell brand-name Wegovy through NovoCare Pharmacy at $599/month. Ten weeks later, on June 23, 2025, Novo terminated the partnership in a public press release naming Hims's "illegal mass compounding and deceptive marketing" as the reason. Hims's share price fell roughly 30% on the day; securities class actions followed within 48 hours.

The disagreement was structural. Novo's reading was that Hims used the personalisation framing to keep mass producing compounded semaglutide while selling the brand alongside. Hims's reading was that it was operating inside §503A(b)(1)(D). The dispute lasted eight months and ended in the patent suit, the settlement, and the March 2026 product pivot.

What a Hims patient is actually paying for

There are three cost components worth separating in your head before you fill in any intake form.

• The drug itself. As of May 2026 this is Wegovy (oral or injectable) or Ozempic. The list price is Novo's, not Hims's. The medication-only component is $149/month (oral Wegovy) or $199/month (injectable Wegovy). Whether Hims is a meaningful discount on buying direct from NovoCare is the comparison a careful reader should make; see our Wegovy cost page for the NovoCare direct numbers.
• The clinician consultation. The asynchronous prescriber interaction, the prescription itself, and any follow-up adjustments. This is bundled into the membership fee rather than disclosed as a separate line item.
• The membership/subscription overhead. A mandatory recurring platform fee on top of the medication: $39 for the first month, $149/month on auto-renewal. At steady state, the membership fee equals the entire medication headline price — which is why the total-cost arithmetic is easy to miss at sign-up.

What we would watch for, signing up today

When we run the hands-on intake, here is what we will be looking at. These are also the five things a careful reader should check directly.

1. Cancellation friction. What does it take to cancel mid-cycle or after one shipment? Completable in-app, or phone call / written request? Any clawback after the discounted introductory month? Reddit threads suggest this is the most common operational complaint about Hims — verify the cancellation path before you start.
2. Named clinician versus anonymous medical team. Does the intake assign you a specific prescriber by name, or route you to a generic "medical team"? The latter is allowed but it is a meaningful difference for follow-up continuity.
3. Refill cadence and dose-increase paperwork. When does the next shipment arrive and at what dose? At the step from starter to maintenance dose, what does the documentation actually say?
4. What the personalised-dose paperwork says (if any). Where a compounded product is still offered to transitioning patients, the prescriber file is required to document a clinical reason the FDA-approved version does not suit. Is that on a record you can retrieve, or is it implicit?
5. Contraindication screening at dose increase. Does the intake screen for the Wegovy label contraindications (personal or family history of medullary thyroid carcinoma, MEN 2, pancreatitis, gallbladder disease, severe gastroparesis) and adjust if any are flagged?

Our long-form scoring rubric is on the methodology page.

The off-ramp question

Hims has not publicly published a tapering or discontinuation protocol as of May 2026. That is worth naming.

The clinical literature shows substantial weight regain in the year after stopping a GLP-1; STEP 4 randomised semaglutide-to-placebo patients regained around two-thirds of their lost weight over 48 weeks. A subscription provider whose revenue depends on monthly refills has limited incentive to publish a step-by-step protocol for stopping, and Hims is not the only one in the category that has not. We will ask at the hands-on stage whether a written taper plan is provided on request. The published off-ramp evidence lives at our stopping-Wegovy summary once it clears medical review.

How we keep this article current

We refresh this page on a re-filed Novo lawsuit, a change to Hims's GLP-1 product mix, a change to published pricing, or a new FDA warning letter to Hims or Hers. Two things move fastest:

• The settlement terms. The March 9, 2026 settlement reserved Novo's right to refile. If Hims is found to be advertising compounded GLP-1 products in breach of the terms, the patent suit can be re-filed and the product mix can shift again on a court-ruling timetable.
• Pricing. The $149/month Wegovy-oral-pill headline is a medication-only price; the $149/month membership fee is separate, and Novo's underlying list price is the rate that will matter for a patient who stays on treatment past the introductory window — and Novo's price can move. The hands-on update will be added as a dated block at the top of the page when our editorial team has run the intake end to end. For a head-to-head comparison with Hims's closest branded competitor, see our Ro Body review and the Hims vs Ro comparison.

If you spot an error or a missing source, email [email protected]. Broader regulatory context sits on the compounding cliff timeline and the provider-status tracker.